Slate Medicines doses first participant in Phase 1 trial of migraine antibody SLTE-1009

PUBT · 3d ago
Slate Medicines doses first participant in Phase 1 trial of migraine antibody SLTE-1009
  • Forbion portfolio company Slate Medicines dosed the first participant in a Phase 1 study of SLTE-1009 for migraine prevention.
  • Trial in healthy volunteers in Australia tests single-ascending doses, multiple-ascending doses, safety, pharmacokinetics.
  • Topline safety results, pharmacokinetic data expected in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.